Drug profile · INN
hydrocortisone sodium succinate
SOLU-CORTEF
hydrocortisone sodium succinate (SOLU-CORTEF) is a glucocorticoid receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — hydrocortisone sodium succinate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
hydrocortisone sodium succinate (SOLU-CORTEF) is a glucocorticoid receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is hydrocortisone sodium succinate?
hydrocortisone sodium succinate (SOLU-CORTEF) is a glucocorticoid receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for hydrocortisone sodium succinate?
SOLU-CORTEF is a marketed brand name for hydrocortisone sodium succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of hydrocortisone sodium succinate?
hydrocortisone sodium succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.